Since the last consensus conference 2018 new drugs have come to patients and have been examined in prospective trials (f.e. nirogacestat, MTX/VIN vs pazopanib). An independent institute should analyze available data. Which medical treatments can be classified as active in desmoids and can a hierarchy of use of drugs be generated according to efficacy and toxicity. The latter is an important aspect from the patients’ view.
Re-analysis of existing evidence (since 2018) with particular focus to results of recently conducted and published trials on medical treatment. A couple of recently conducted randomized trials and single-arm trials need to be evaluated with respect to efficacy versus toxicity of medical treatment